D R Abernethy
Overview
Explore the profile of D R Abernethy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
221
Citations
2683
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gronich N, Lavi I, Barnett-Griness O, Saliba W, Abernethy D, Rennert G
Br J Cancer
. 2017 Apr;
116(10):1366-1373.
PMID: 28399109
Background: The impact of cancer therapies on cardiac disease in the general adult cancer survivor population is largely unknown. Our objective was to evaluate which tyrosine kinase-targeting drugs are associated...
2.
Musante C, Abernethy D, Allerheiligen S, Lauffenburger D, Zager M
CPT Pharmacometrics Syst Pharmacol
. 2016 Sep;
5(9):449-51.
PMID: 27639191
Quantitative Systems Pharmacology (QSP) is experiencing increased application in the drug discovery and development process. Like its older sibling, systems biology, the QSP field is comprised of a mix of...
3.
Yoshida K, Sun B, Zhang L, Zhao P, Abernethy D, Nolin T, et al.
Clin Pharmacol Ther
. 2016 Jan;
100(1):75-87.
PMID: 26800425
Recent reviews suggest that chronic kidney disease (CKD) can affect the pharmacokinetics of nonrenally eliminated drugs, but the impact of CKD on individual elimination pathways has not been systematically evaluated....
4.
Shon J, Abernethy D
Clin Pharmacol Ther
. 2014 Oct;
96(5):536-7.
PMID: 25336266
Advances in systems biology have allowed the development of a highly characterized systems pharmacology model to study mechanisms of drug-induced hepatotoxicity. In this issue of CPT, Yang et al. describe...
5.
Sarntivijai S, Abernethy D
Clin Pharmacol Ther
. 2014 Jul;
96(2):149-50.
PMID: 25056395
Internet search logs provide an abundant source of data that can be explored for purposes such as identifying drug exposure-adverse event relationships. The methodology to rigorously conduct such evaluations is...
6.
Needs for an expanded ontology-based classification of adverse drug reactions and related mechanisms
Zhichkin P, Athey B, Avigan M, Abernethy D
Clin Pharmacol Ther
. 2012 May;
91(6):963-5.
PMID: 22609907
The growing significance of bioinformatics and systems biology in drug safety research requires a system of adverse-event classification that goes beyond a simple vocabulary. This opinion piece outlines the need...
7.
Gnjidic D, Hilmer S, Blyth F, Naganathan V, Cumming R, Handelsman D, et al.
Clin Pharmacol Ther
. 2012 Feb;
91(3):521-8.
PMID: 22297385
Evidence about the association between treatment with high-risk medicines and frailty in older individuals is limited. We investigated the relationship between high-risk prescribing and frailty at baseline, as well as...
8.
Abernethy D, Bai J, Burkhart K, Xie H, Zhichkin P
Clin Pharmacol Ther
. 2011 Oct;
90(5):645-6.
PMID: 22012310
The rapid evolution of large biological, pharmacological, and chemical databases has led to optimism that such data resources can be leveraged for prediction of drug action based on molecular descriptors...
9.
Abernethy D, Woodcock J, Lesko L
Clin Pharmacol Ther
. 2011 Apr;
89(6):793-7.
PMID: 21490594
Advances in cheminformatics, bioinformatics, and pharmacology in the context of biological systems are now at a point that these tools can be applied to mechanism-based drug safety assessment and prediction....
10.
Abernethy D, Burckart G
Clin Pharmacol Ther
. 2010 Feb;
87(3):270-1.
PMID: 20160747
Selection of a drug dose in pediatrics is generally based on no or incomplete pharmacokinetic data. Traditionally, allometric, or scaling, techniques have been used; however, they have inherent limitations and...